Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ESBATech AG

Division of Alcon Inc.
www.esbatech.com

Latest From ESBATech AG

On The Path To Regeneration: NovaGo’s New Approach To Stroke

Zurich University spin-off NovaGo Therapeutics is taking a regenerative approach to stroke, and with €10m funding from a series A round to proceed its preclinical asset into Phase I, it is hoping to be in the clinic within two years.

Regenerative Medicine StartUps and SMEs

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Deals M & A

Deal Watch: Denali Partners With Sirion To Take On The Blood-Brain Barrier

Denali will collaborate with Sirion in Parkinson’s and Alzheimer’s diseases. Meanwhile, Lundbeck and Elevian unveil drug development partnerships with technology firms at the J.P. Morgan meeting.

Deals Business Strategies

Alcon reports positive data with potential Eylea competitor

Alcon, Novartis's ophthalmic business, has reported positive results from a Phase II study of RTH258, which it is developing to compete against Regeneron Pharmaceuticals' Eylea (aflibercept). RTH258 has already entered Phase III testing.

See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Alcon Inc.
  • Senior Management
  • Dominik Escher, PhD, CEO
    Martin Gertsch, CFO
    David Urech, PhD, Head, R&D
  • Contact Info
  • ESBATech AG
    Phone: (41) 44 733-4900
    Wagistr. 21
    Zurich-Schlieren, CH-8952
    Switzerland
UsernamePublicRestriction

Register